Floatz logo

Shr-8068

Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk cohort.

Asset / SponsorPhaseRating
Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2CCC

Same molecule, other indications

Shr-8068 is also rated in:

Advanced Non-small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
Malignant Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →